Oryzon Genomics

• Private Placement of 7,273,000 shares, 15.9% of Oryzon Genomics’ outstanding share count, at a price of €2.75 per share
• Gross proceeds amounted to €20m, which will be used to progress product candidates in central nervous system and oncology indications
• Proceeds are expected to be used for the advancement of clinical programmes including the Phase IIb trial in BPD adult patients to treat agitation‐aggression, the extension of the Phase II trial in acute myeloid leukaemia and the extension of the Phase II trial in small cell lung cancer
• This transaction marks Kempen & Co’s 7th transaction for European life sciences companies since the beginning of 2020 and our first ever transaction for a Spanish life sciences company, underpinning our ambition to work with innovative life sciences companies across all of Europe

Oryzon is a leading European epigenetics biotechnology company developing a portfolio of products focused on the central nervous system and oncology around LSD1 (the most abundant enzyme in the human frontal cortex). The Company has recorded positive clinical efficacy data in initial trials across all indications that it is targeting. Most recently the Company reported positive efficacy data in acute myeloid leukaemia in June 2020 where their product, iadademstat, in combination with azacitidine in elderly patients demonstrated an overall response rate of 77% (10 out of 13 evaluable patients), of which 60% are in complete remission. Additionally, the Company reported positive data from its aggression study in Alzheimer’s disease in April 2020 which showed that the product is safe and well tolerated and also led to a significant reduction of agitation-aggression after 6 months of treatment. The Company plans to initiate Phase IIb trials with its lead product for the treatment of aggression in borderline personality disorder in Q1 2021.

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent, Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia, Co-Manager in the USD 862 million Global Offering by argenx, Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides, Co-Manager in the USD 154 million Global Offering of DBV Therapeutics, Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical, Lead Manager in the USD 557 million Global Offering by argenx, Co-Manager in the USD 79.2 million US Public Offering by Merus, Co-Manager in the USD 57.5 million Capital Increase by ProQR, Co-Manager in the USD 150 million Nasdaq IPO of BioNTech, Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth, Co-Manager in the USD 20 million Global Offering of Celyad, Co-Manager in the USD 582 million NASDAQ IPO of Genmab, Joint Bookrunner in the €116 million Secondary Sale of Fagron shares by Waterland and Baltisse, Joint Bookrunner in the €48.7 million Rights Issue by Transgene and Joint Bookrunner in the SEK 727 million Capital Increase by Oncopeptides.